Pricing & Reimbursement

Pricing & Reimbursement

  • Parexel Analyzes the Real-World Data Revolution and Role of Early Payer Engagement2:21

    Parexel Analyzes the Real-World Data Revolution and Role of Early Payer Engagement

    Richard Tolley, Vice President Integrated Market Access Solutions at Parexel discusses a recent roundtable discussion about the role of early payer insights in real-world data studies.

    Watch Video
  • See how our experts can add value to your strategy

    Learn More ►
  • Get your free evidence readiness score today!

    Take Assessment
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How

    Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How

    Learn about the need for innovation in global reimbursement mechanisms, the potential risks and benefits of implementation, and real world examples in a presentation by PAREXEL Access Consulting Exper

    View Presentation
  • The FDA Approval of Eteplirsen: Necessary Flexibility or Worrying Precedent? Poster

    The FDA Approval of Eteplirsen: Necessary Flexibility or Worrying Precedent? Poster

    Read More
  • Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

    Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

    View Now
  • Presentation Slides: Early Engagement Strategies Webinar

    Presentation Slides: Early Engagement Strategies Webinar

    View Now
  • The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

    The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Read More
  • CADTH's $50,000 Cost-Effectiveness Threshold: Fact or Fiction?

    CADTH's $50,000 Cost-Effectiveness Threshold: Fact or Fiction?

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017

    Read More
  • ×

    Tell Us About Your Market Access Nightmares.

    What keeps you up at night?
    Thank you!
    Error - something went wrong!
  • Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

    Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • loading
    Loading More...